Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis of major clinical trials

American Journal of Medicine

Volumn 109, Issue 3, 2000, Pages 213-217

  Memon, Mumtaz A ^a   Blankenship, James C ^a   Wood, G Craig ^a   Frey, Carolin M ^a   Menapace, Francis J ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; PLACEBO; TIROFIBAN;

ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INCIDENCE; PRIORITY JOURNAL;

ACETATES; ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; ODDS RATIO; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; SYNDROME; TYROSINE;

EID: 0034663250     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00453-8     Document Type: Article

References (17)

1. Theroux P., Kouz S., Roy L., et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina the Canadian lamifiban study . Circulation. 94:1996;899-905.
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
3. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin duration percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
4. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 352:1998;87-92.
5. Brener S.J., Barr L.A., Burchenal J., et al. A randomized, placebo-controlled trial of abciximab with primary angioplasty for acute MI the RAPPORT trial . Circulation. 98:1998;734-741.
6. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study . Lancet. 349:1997;1429-1435.
7. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation. 97:1998;2386-2395.
8. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 338:1998;1498-1505.
9. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. NEJM. 338:1998;1488-1497.
10. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339:1998;436-443.
11. Tcheng J.E., Harrington R.A., Kottke-Marchant K., et al. Multicenter randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation. 91:1995;2151-2157.
12. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II . Lancet. 349:1997;1422-1428.
13. Effect of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
14. Kereiakes D.J., Kleiman N.S., Ambrose J., et al. Randomized, double-blind, placebo controlled dose ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 27:1996;536-542.
15. Blankenship J.C. Bleeding complications of glycoprotein IIb/IIIa receptor inhibitors. Am Heart J. 138:1999;S287-S296.
16. Vahdat B., Canavy I., Fourcade L., et al. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Cathet Cardiovasc Intervent. 49:2000;177-180.
17. Gart J. Point and interval estimation of the common odds ratio in the combination of 2×2 tables with fixed margins. Biometrika. 57:1970;471-475.